Quick Answer
Summit Therapeutics Inc. reported R&D Expense of $59.47 million for fiscal year 2023.
Summit Therapeutics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2023 | $59.47M | +14.4% |
| 2022 | $52.00M | -39.1% |
| 2021 | $85.35M | +60.2% |
| 2020 | $53.27M | +33.8% |
| 2019 | $39.81M | -23.4% |
| 2019 | $52.00M | +79.5% |
| 2018 | $28.98M | +52.9% |
| 2017 | $18.95M | +12.4% |
| 2016 | $16.86M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2024 | $30.87M | +212.4% | +101.5% |
| September 30, 2023 | $15.32M | -10.1% | +62.1% |
| June 30, 2023 | $9.45M | +4.9% | -4.4% |
| March 31, 2023 | $9.88M | -51.9% | -42.0% |
| September 30, 2022 | $17.05M | -14.5% | +89.3% |
| June 30, 2022 | $9.01M | -62.3% | -56.2% |
| March 31, 2022 | $20.56M | +11.8% | +3.1% |
| September 30, 2021 | $19.94M | +45.3% | -16.6% |
- Summit Therapeutics Inc. showed an increase of +14.4% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2023 period, Summit Therapeutics Inc.’s r&d expense has grown by 252.8% (from $16.86 million to $59.47 million).
- The most recent figure is from Summit Therapeutics Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on February 20, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: